Tetra Radar · FDA Approvals · Decision date
garetosmab: FDA decision date
Regeneron Pharmaceuticals Inc (REGN) · August 2026
In February 2026, the FDA accepted for priority review the Biologics License Application (BLA) for garetosmab (an Activin A antibody) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), which has a target action date in August 2026.
Source: 8-K of 29 April 2026
The date has passed; Tetra Radar has not recorded an approval.
Regeneron Pharmaceuticals Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.